SCHEMBL3230353

SCHEMBL3230353

C=C(C)OCC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
EPHX1 P07099 1/20 0.36
SLC1A3 P43003 3/20 0.34
SLC1A2 P43004 3/20 0.34
SLC1A1 P43005 3/20 0.34
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSK P43235 1/20 0.33
CYP1A2 P05177 1/20 0.33
PARP15 Q460N3 1/20 0.33
PARP10 Q53GL7 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19540992 0.88 ALDH1A1 (0.33) LMNA
SCHEMBL23675573 0.88 ALDH1A1 (0.33) LMNA
SCHEMBL23675571 0.88 ALDH1A1 (0.33) LMNA
SCHEMBL28647347 0.80 ESR1 (0.31)
SCHEMBL6081993 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL15608263 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL8408212 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL23493948 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL5936685 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL105131 0.79 ALDH1A1 (0.55) LMNAEPHX1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858670-B2 Photosensitive inkjet ink TOSHIBA TEC KABUSHIKI KAISHA (JP) 2010-12-28 US disclosed
US-7858670-B2 Photosensitive inkjet ink TOSHIBA TEC KABUSHIKI KAISHA (JP) 2010-12-28 US disclosed
US-7745438-B2 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors ELI LILLY AND COMPANY (US) 2010-06-29 US disclosed
US-20100026771-A1 INKJET RECORDING METHOD, INKJET RECORDING SYSTEM, AND PRINTED MATERIAL FUJIFILM CORPORATION (JP) 2010-02-04 US disclosed
US-20100026771-A1 INKJET RECORDING METHOD, INKJET RECORDING SYSTEM, AND PRINTED MATERIAL FUJIFILM CORPORATION (JP) 2010-02-04 US disclosed
EP-2149457-A2 Inkjet recording method, inkjet recording system, and printed material Fujifilm Corporation (JP) 2010-02-03 EP disclosed
US-20090234040-A1 ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, STORAGE CONTAINER FOR ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, AND METHOD FOR STORING ACTIVE ENERGY RAY-CURABLE INK COMPOSITION KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-09-17 US disclosed
US-20090234040-A1 ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, STORAGE CONTAINER FOR ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, AND METHOD FOR STORING ACTIVE ENERGY RAY-CURABLE INK COMPOSITION KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-09-17 US disclosed
US-7473720-B2 Photosensitive inkjet ink TOSHIBA TEC KABUSHIKI KAISHA (JP) 2009-01-06 US disclosed
US-7473720-B2 Photosensitive inkjet ink TOSHIBA TEC KABUSHIKI KAISHA (JP) 2009-01-06 US disclosed
US-7375145-B2 capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound TOSHIBA TEC KABUSHIKI KAISHA (JP) 2008-05-20 US disclosed
EP-1528088-B1 Inkjet ink TOSHIBA TEC KK (JP) 2008-02-27 EP disclosed
US-20070270520-A1 Capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound RISO TECHNOLOGIES CORPORATION (JP) 2007-11-22 US disclosed
US-20070270520-A1 Capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound RISO TECHNOLOGIES CORPORATION (JP) 2007-11-22 US disclosed
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070185224-A1 PHOTOSENSITIVE INKJET INK KABUSHIKI KAISHA TOSHIBA (JP) 2007-08-09 US disclosed
US-20070185224-A1 PHOTOSENSITIVE INKJET INK KABUSHIKI KAISHA TOSHIBA (JP) 2007-08-09 US disclosed
US-20070101898-A1 Inkjet ink AKIYAMA RYOZO 2007-05-10 US disclosed
US-20070101898-A1 Inkjet ink AKIYAMA RYOZO 2007-05-10 US disclosed
WO-2003062265-A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors BACE1, BACE2, APP LMNA 877/4885EPHX1 209/4885SLC1A3 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.